

2022.03.11

Skunkworks Project: Radegen Bio's Enzymatic Toolkit [CC BY-NC-SA 4.0](#)

Fernando Andrade, M.S.,

Director the Skunkworks Division, Founder and CEO of Radegen Bio. www.radegenbio.com

Introduction:

The Radegen Bio Forging toolkit consists of a full suite of nucleic acid manipulation factors. The kit includes several ligases, polymerases, restriction enzymes, and molecular reporter proteins. Here a description, characterization and expression constructs are provided to be used for wet lab R&D. DNA binding proteins have similar characteristics that allows Radegen to use a common His-tag based for protein purification. Based on my analysis of the literature, it seems that there is a preference for protein purification of DNA binding enzymes. Polymerase preparation techniques use heat based purification using different columns to first denature the majority of the *E. coli* proteome leaving only enzymes that do not denature in high heat environments. This is the reason why polymerases are derived from thermophilic archaea. This method is more costly because it produces waste since there will be a percentage of enzyme loss during heating, and after running the preparation through multiple columns. A simpler and proven method for purifying proteins is needed that facilitates design but also allows for easy purification. A paper was identified, searching for clues of original methods that may have been adopted for large scale purification. A purification tag was found that was published by Dabrowski, S. and J. Kur (1998) that demonstrates a method that improves on previous tag-based protein methods that includes a 43 amino acid N-terminal tag that results in a protein with 700,000 U per mg. The 43 aa tag improved unit yield by 600,000 units per mg over previously reported methods. An observation made after this find suggest that the his-tag may change the conformation of the peptide since the projection point may embed the his-tag at least 1 residue. This method is employed by Radegen for DNA binding proteins, the 43 aa tagged is termed Theta+43 domain, a proprietary feature of Radegen Bio's toolkit that provides a competitive advantage since purification is more efficient and less costly. The tag has been shown to not effect activity of a sensitive protein this much is clear since the majority of sources avoid their use. Simply extending the tag sufficiently may be an excellent method for purifying the majority of soluble proteins.

Development of this toolkit allowed me to contemplate how a synthetic biology researchers or companies are to deal with creating work with intellectual property that by themselves are a monumental task but are derived from publicly available sources. Today's work involves creating novel systems based on 70 year's worth of work and there is a plethora of ideas that may have been overlooked or simply forgotten. Synthetic Biologist have tasked themselves to use the collective knowledge up to date to form new function out of nature. The applications for this branch of science is literally world saving and the legacy model of intellectual property hoarding by major biotech corporations has promoted an unethical culture in biotech today. We have all experienced the demise of a colleague after sharing an idea. Oftentimes were left desperate when we have that one in a million idea and don't know what to do with it and feed our families at the same time. The United States academic community has literally trained the world in the life science discipline and it requires a special lineage to produce a scientist with a comprehensive education to be able to first identify an interesting topic or problem, indicating the logic required to process the idea to begin with. The world has not propose such venture and stated it to be impossible. Enzymatic DNA synthesis is possible and here I report on enzymes that can be used for this purpose.

Keeping in mind the nature of open source biology, it is important to acknowledge that The American Society for Microbiology, under the direction of Sam Kaplan brought microbiology to the world because the world needed it by focusing his efforts on disseminating information via ASM publications. Microbiologist trained in molecular genetics are perfectly suited for both developing and working in settings that produce completely sustainable synthetic DNA using *E. coli* as the production chassis, and the tools developed from the work of ASM members. Samuel Kaplan achieved in two key areas, he mad ASM what it is today by ensuring the dissemination of information for advancing the art, and developing a Microbiology and Molecular Genetics Department with all the correct areas of expertise from literal world leaders in their field. Sometimes ideas are forehead slapping and other times they take expert training in systematic approaches to addressing problems.

Here, I specifically present the application of rational design for engineering synthetic proteins. A description of each one is provided and its specific use. I am proud to announce that I have decided to protect this publication by CC BY-NC-SA 4.0 Creative Commons licensing architecture since improvements can be made over the concepts created here. Strategies and sequences not previously employed by intellectual property protection are free to be modified and shared under the same terms meaning that if you have intellectual property that is derived from this work, then you can modify with attribution for non-commercial use. In this case I do see, as anyone else would a few improvements that can be made. Industry can get licensing rights to use the novel enzyme described here and make modification under explicit permission since this license both protects the rights of a licensee and licensor. For example, after expiration of a license, one can then re-license a protected item to someone else. This structure guarantees that the work started under an open-source culture is always maintained since improvements are published with the same license, remain open source for non-commercial use but protects the rights of the licensor for exclusive use of the approved improvement. Commercial entities cannot begin an improvement process before negotiating an improvement and compensation over the course of the licensing terms. Legal term presented here is part of this creative work and this statement although indeed a mask for using this approach for intellectual rights protection. Litigation will be a an act of corporate extortion directly directed to the scientific community that first made the discoveries that most molecular microbiologist simply know like the back of their hand. The synthetic biology discipline, one that is currently almost exclusively staffed with academics are genuinely forming a new reality with concepts that result in wonderful work with commercial potential. Protection is required because it take decades of work to even know enough to identify that there is a problem or that a novelty is genuine. Any protest to works coming from corporate biotech against an open source company will be laughed at since support for the corporate giant, that relies on bully tactics to convince others that their ideas are not novel or to simply steal a laptop rely on breaking the law in every way imaginable. Some of the most brilliant minds have the potential of being in jeopardy for simply being brilliant.

This document provides a detailed description of the Theta+ molecular toolkit along with details and results of the *in silico* development of the toolkit. This document contains trade secrets and is protected under copyright and trademark protection.

The Theta+ Polymerase Suite: This set of enzymes is composed of one high fidelity and one low fidelity polymerases with improved processivity and efficiency. In a PCR reaction they both have fidelity rates similar to the native enzyme but have faster reaction rates and are able to polymerize larger DNA fragments. Both polymerases have processivity values of 0.98 (Microscopic processivity (PI)^a and both extend primers by 55 nt per protein/DNA binding event (PI) (Average primer extension length (nt) [1/(1 + PI)]^a). This feature allows PCR reactions to have the same thermocycling program regardless of the polymerase being used. This system also includes a terminal 5' - 3' polymerase used in *de novo* DNA forging. The Theta43 domain unifies all proteins described here into a common system.

1. **ThetaPfu+S Polymerase** – An enzyme based on an open-source Pfu polymerase first isolated from *Pyrococcus furiosus*. The enzyme is an archaeal chimera fusing Pfu with a thermo stable non-specific DNA binding peptide, Sso7 from *Sulfolobus solfataricus*. This fusion protein has the same fidelity as Pfu but with improved efficiency. ThetaPfu-S Pol. is a proprietary next-generation Pfu polymerase that is used across all production and R&D applications at Radegen Bio. a. **Error rate:** 2.8×10^{-6} (one error every 2.8 million bp)

- b. **Notable features:** 5' - 3' polymerization; 3' - 5' exonuclease activity; max length: 15kb; efficiency: 10kb with 1 min extension time.
- c. **Published reaction conditions for PCR:** PCR buffer contained 20 mM Tris-HCl pH 8.8, 10 mM (NH4)2SO4, 0.1% Triton-100, 2 mM MgCl2 and 200 mM each dNTPs with 10 mM KCl for Pfu and 60 mM KCl for Pfu-S. The cycling protocol was 95°C for 20 s; 20 cycles of 94°C for 5 s and 72°C for 30 s (A) or for 60 s (B) or for 2 min (C); 72°C for 7 min.
- d. **Efficiency :** when 10 U/ml Pfu-S was used, the same 5 kb target can be amplified with a 30 s/cycle extension time. When a 2 min/cycle extension time was used, products as long as 15 kb were clearly detected with Pfu-S. 1kb/8 sec

2. **ThetaTaq+S Polymerase** – An enzyme based on an open source Taq polymerase first isolated from *Thermococcus aquaticus*. The enzyme is an archaeal chimera fusing Taq with a thermo stable non-specific DNA binding peptide, Sso7 from *Sulfolobus solfataricus*. This fusion protein has the same fidelity as Taq but with improved efficiency. ThetaTaq-S Pol is a proprietary next-generation Taq polymerase that is primarily used for analytical techniques like qPCR or running an agarose gel. ThetaTaq-S maintains A-tailing activity and is an important molecular tool for applications like TA cloning.

- a. **Error rate:** 5.6×10^{-5} (one error every bp 560,000)
- b. **Notable features:** 5' - 3' polymerization; 5' - 3' (exo-); 3' - 5' (exo-); max length: 5kb;
- c. **Published reaction conditions for PCR:** The PCR buffer contained 10 mM Tris-HCl pH 8.8, 2 mM MgCl2, 200 mM each dNTPs and 0.1% Triton-100 with 10 mM KCl for Taq(D289) and 50 mM KCl for S-Taq(D289) and Taq. The cycling protocol was: 95°C for 20 s; 20 cycles of 94°C for 5 s and 72°C for 30 s (A) or for 60 s (B) or for 2 min (C); 72°C for 7 min.
- d. **Efficiency:** 20 U/ml enzyme and a 1 min/cycle extension time amplified a 5 kb target; 1kb/12 sec

3. **ThetaDtd+ Polymerase** – An enzyme based on an engineered dTd from terminal deoxynucleotidyl transferase from *Zonotrichia albicollis*, TdtR335L-K337G. This peptide is further engineered with the addition of the Theta43 tag and C to A mutations in all but 3 cysteine residues. This is a completely novel proprietary DNA polymerase used in Radegen Bio's *de novo* DNA forging system. This enzyme is amenable for both Dtd-dNTP conjugate *de novo* synthesis and Dtd *de novo* synthesis using dNTPs protected on the 3' OH group by a ONH2 group. 5 versions of the polymerase were developed to include 2 ThetaDtd+ fused with SsoT and 2 ThetaDtd+ fused with Ssod7. All 4 enzymes will be tested for improved *de novo* strand elongation in terms of processivity and efficiency using both dNTP protective strategies.

- a. Radegen Bio ssDNA synthesis platform is a revolutionarily simple and robust DNA synthesis platform that uses a genetically engineered terminal deoxynucleotidyl transferase from *Zonotrichia albicollis*, ThetaTdt+ and was wholly developed by the Radegen Bio Skunkworks division. This platform can generate dsDNA fragments >200 bp. The fragments produced by this process are used by Radegen Bio for the *de novo* construction of circular DNA preps. It's simplicity lies in the use of standard liquid handling robotics designed for preparing DNA preps using magnetic beads (dedicated custom design instrumentation is being investigated for feasibility and cost). The system is based on a 96 well format microtiter plate footprint since the processivity per plate is faster with smaller scales of individual reactions. Since a standard Eppendorf liquid handling robot is a fraction of the cost (< \$10,000 USD) compared to all DNA synthesis instruments currently sold, this approach allows for scaling of yield by using multiple liquid handling units. Pipet tip consumption can be minimized by using tips multiple times. The synthesis reaction occurs on a priming ssDNA oligo substrate, termed eGATTACA_N and with a sequence identity of 5' - (Gattaca)_N - 3' that is tethered to 1 micron streptavidin coated magnetic bead via a 5' linked biotin group. The reaction substrate is added to the wells of a 96 well plate designed for silica-based DNA purification. The reaction can also be carried out in a 96 well plate with the use of a magnetic module in the robotic liquid handler. The reaction commences with the addition of a protected dNTP (3'-ONH2-dNTPs (Firebird Biomolecular Sciences, LLC, US) or a dNTP-Dtd conjugate; both protects the 3' end of the elongating strand after incorporation of the dNTP and with eTdt. The reaction is incubated at 30°C for 10 min followed by a wash step to remove the polymerase and excess dNTP. The ONH2 or Dtd protective group is then removed by treatment with a sodium nitrite buffer followed by a wash step to remove deprotection buffer. These

steps are repeated until the desired DNA molecule is elaborated. After the polymerization steps are complete the magnetic beads are resuspended and removed from the reaction plate and transferred to a 96 well plate PCR plate. dsDNA libraries are made using a universal primer sequence that binds to a termina adaptor at the end of the ssDNA tethered to the magnetic beads and a primer binding site found on ϕ gattaca_N priming tethered oligo. The dsDNA prep is then removed using magnetic bead purification. **This process is referred to as DNA forging since it differs from processes that use chemical synthesis. Chemical synthesis relies on the reactivity of a reactive functional group produced by the chemical conditions of the buffers used (such as pH or the presence of a chemical catalyst) in each elongation step. Enzymatic DNA synthesis is more akin to a forging process since the enzyme needs to make physical contact (like a hammer striking metal to forge a functional structure) to complete an extension step.** Thus, **e+ dna (Theta plus DNA) forging is a proprietary enzymatic de novo stepwise DNA synthesis system that produced dsDNA preps with fragment length > 200 bp and composed of a distinct desired sequence. The dsDNA fragment preps produced by the eRadegen Bio Foundry are intended for use in the forging of circular DNA molecules. Theta+ de novo DNA Forging was conceived and developed by the CSO/CEO of Radegen Bio, Fernando Andrade, M.S.** and is described here for the first time, is proprietary and for the exclusive use by the eRadegen Bio dsDNA Foundry. This system will not be sold nor described to the public aside from the bold red text above. The rational for calling Radegen Bio's DNA synthesis process "forging" can be disclosed to the public with the sentence above in bold blue text.

4. **ThetaPfUTPase** – An enzyme based on a open source dUTPase that enhances the Theta+ Archaeal Pol performance in terms of larger yields and maximum fragment size. This occurs by degrading dUTP, preventing Theta+ Archaeal Pol. from incorporating dUTP into an amplifying fragment. dUTP incorporation inhibits further dNTP incorporation and is problematic enough with Pfu based polymerase that the presence of dUTP has a drastic impact on DNA yield. Theta+ PfUTPase is a proprietary enzyme used in enzymatic cocktails for building DNA constructs > 15,000 bp.
5. **Theta+SsoT** – a ssDNA binding protein shown to enhance processivity of DNA polymerase. This peptide can be added to a PCR reaction to improve yield and processivity. The Theta+ polymerase suite has 2 Tdt-SsoT Fusion polymerases (proprietary) for use in dsDNA forging.
6. **Theta+TEV** – a protease used in protein purification process and complementary to the Theta43 Tag.
7. **Theta+Sso7d** – a dsDNA binding protein shown to enhance processivity of DNA polymerase. This peptide can either be fused to either the N or C terminus of a polymerase and has be shSown to increase efficiency in terms of yield and maximum fragment length.
8. **Theta43 domain** – A multipurpose purification tag that has been shown to maintain normal function of DNA binding proteins, specifically DNA polymerases. Comparison between this 43aa domain and a previously reported 12 aa tag showed that the shorter tag had an inhibitory effect while the 43 aa tag was benign. This tag provides a 6x His tag, a thrombin cleavage site, an S-tag, and a TEV site that produces a tag-less protein.
9. **Theta+ISO** – Based on an open source iso-thermal polymerase first isolated from *Bacillus stearothermophilus*. High fidelity Bst. It has an error rate of about 7.8x10⁻⁷, a fidelity about 20 times higher than standard Bst, and better than Phusion in High-GC buffer. The specifically patented enzyme is the polymerase, which is a NEB proprietary strand displacing polymerase with high fidelity. Luckily Bst-HF is precisely that, a high-fidelity strand displacing polymerase. The kit is supposed to run at 50°C (-60°C), which also happens to be within the optimal temperature range for Bst. One other use for Bst-HF, or even better fusion variants on a Taq scaffold of that enzyme, would be for high-GC sequences. The addition of a bit of thermotolerant strand displacing polymerase lets one amplify DNA sequences with well over 80% GC with ease, and boosts amplification of large fragments due to its' ability to overcome complex/problematic sequences
10. **Theta+EXO** – Based on a 5' – 3' exonuclease first isolated from T5 bacteriophage.
11. **Theta+LGT** – Based on a thermo stable ligase first isolated from *Thermophilus aquaticus*.

The data provided below provides data performance improvements that result from adding a DNA binding peptide to PCR.




Figure 1. Agarose gel electrophoresis analysis of PCR efficiencies for Pfu, Pfu-S, Taq, Taq(Δ289), Taq-S and Taq(Δ289)-S. A. Comparison between Pfu and Pfu-S of total PCR product generated as a product of extension time and template length. Pfu-S amplifies DNA templates > than 5kb under conditions where extension times are greater than 60 seconds. Wild-type Pfu does not exhibit amplification of targets greater than 5 kb under 2 min and 7 min extension length conditions. B. Agarose gel electrophoresis analysis determining salt tolerance of the tested polymerase variants. Mutants augmented with the Ssod7 domain had an increased tolerance to KCl up to 120 mM and concentrations above this threshold resulted in polymerization abolition instead of a gradient decrease. A. Comparison between Taq, Taq(Δ289), Taq-S and Taq(Δ289)-S of total PCR product generated as a product of extension time and template length. Taq(Δ289)-S amplifies DNA templates < or = to 5kb under conditions where extension times are greater than 60 seconds. Wild-type Tan does not exhibit amplification of targets greater than 2 kb under 2 min and 7 min extension length conditions. Taq(Δ289) experienced a general loss of function since there was a loss of fragment size capacity under all conditions, yielding fragments no greater than 1kb regardless of incubation time




Figure 2. A cartoon representation of the ThetaPfu+S expression construct and protein domains. The Pfu+S is a novel 881aa protein containing the Theta43 domain, a polymerase domain from Pfu and a DNA binding domain, ssod7.




Figure 3. 3D model of Pfu showing the native N terminus of the protein and highlighted by a red triangle with the elongated tip pointing at the last residue on the N termini. The N terminus is directed away and towards the surface from the catalytic core. The grey rectangle depicts DNA and is associated to the enzyme structure to illustrate that the catalytic core is on the opposite site of N terminus outward projection point on the top exterior of the enzyme structure. Models for Dtd polymerases did not contain enough N or C terminal residues to make a prediction regarding fusion location relative to the native protein.

In silico development of Theta+ Polymerase suite.

1) ThetaDtd+

The ThetaDtd+ polymerase is a synthetic protein developed from an engineered Dtd polymerase. This enzyme was chosen with the specific aim of finding a Dtd enzyme that was more efficient since a strategy that produces a sustainable method for deprotecting after an elongation step. A protein chaise with improved catalytic rates but with a deprotection methods that left a molecular scar but did not generally interfere with catalysis since a reaction cycle is only 30 seconds. Chemical removal of the protective group on the polymerized strand relies on suppliers. Radegen Bio is committed to sustainable solutions and as company that uses the tools of the molecular biology revolutions, proteases are a preferred method for removing the polymerase from bead bound DNA. This enzyme is versatile since both dntp-polymerase conjugates' or a chemically protected by an o-allyl bond, they can both be removed by UV light or chemicals, making it a lithographic enzyme that is versatile. These enzymes were right under our nose since Dtd are used for tagging the 5' end of an oligo with biotin and sold by Sigma. This Dtd is unique in that it uses the Theta+43 tag in some iterations and combines a enzyme with improved function that resulted from improvements made over wildtype that improve hydrogen binding. Versions containing fusions with 2 archaeal DNA binding proteins, independently of course, to test for novel de facto ligase functionality.

> XM_026799623.1
MDRFKAPAVISQRKRQKGLHSPKLSCSYEIKFSNFVIFIMQRKMGLTRRMFLMELGRRKGFRVESELSDSVTHIVAENNSYLEVLDWLKGQAVGDSSRFELLDISWFTACMEAGRVDSEVKYRLMEQSOSLPLNMPALEMPAFIATKVSQYSCQRKTTNNYNKKFTDAFEVM
AENYEFKENEIFCLEFLRAASLLKSLPFSVTRMKDIQGLPCVGDQVRDIEEEIIIEEGESSRVNEVLNDERYKAFKQFTSVFGVGVTSEKWYRMLRTVEEVKADKTLKLSMQKAGLLYYEDLVSCSKAEADAVSLIVKNTVCTFLPDALVTITGGFRRGKNIGHIDFLIT
NPGPREDDELLHKVIDLWKKQGLLLYCDIIESTFVKEQLPSRKVDAMDHFQKCFAILKLYQPRVDNSTCNTSEQLEMAEVKDWAIRVDLVTIPFEQYPYALLGWTGSRQFGRDLRYYAAHERKMILDNHGLYDRRKRIFLKAGSEEEIFAHGLDYIEPWERNA
>XP_036017403.1 DNA nucleotidylexotransferase isoform X2 [Mus musculus]
MDPLQAVHLGPRKKRPRQLGTPVASTPYDIRFRDLVLFILEKKMGTTTAAFLMELARRKGFRVENELSDS
VTHIVAENNSGSDVLEWLQLQNIKASSELELLDISWLIECMGAGKPVEMMGRHQLVVNRNSSPSPVPGSQ
NVPAPAVKKISQYACQRRTTLNNYNQLFTDALDILAENDELRENEGSCLAFLMRASSVLKSLPFPITSMKD
TEGIPCLGDKVKSIIIEGIIEDGESSEAKVLNDERYKSFKLFITSVFGVGLKTAEKWFRMGFRTLSKIQSD
KSLRFTQMOKAGFLYYEDLVSCVNRPEAEAVSMLVKEAVVTFLPDALVTMTGGFRRGKMTGHDVDFLITS
PEATEDEEQQLLHKVTDFWKQQGLLYCDILESTFEKFKQPSRKVDALDHFQKCFILKLDHGRVHSEKS
GQQEGKGWKAIRVDLVMCPYDRRAFALLGWTGSRFERDLRYYAHERKMMLDNHLYDRTKRVFLEAESE
EEIFAHGLDYIEPWERNA

ClustalOmega Analysis

XM_026799623.1	MDRFKAPAVISQRKRQKGLHSPKLSCSYEIKFSNFVIFIMQRKMGLTRRMFLMELGRRKG	60
XP_036017403.1	MDPLQAVHLGPRKKRPRQLGTPVASTPYDIRFRDLVLFILEKKMGTTTAAFLMELARRKG	60
	** ::* : :*** : * :* * *::*:***:*** *** *****.****	
XM_026799623.1	FRVESELSDSVTHIVAENNSYLEVLDWLKGQAVGDSSRFELLDISWFTACMEAGRVDSE	120
XP_036017403.1	FRVENELSDSVTHIVAENNSGSDVLEWLQLQNIKASSELELLDISWLIECMGAGKPVEMM	120
	****.***** :***:*** : * : **.*****: ** ***:***	
XM_026799623.1	VKYRLMEQSOSLPLNMPA-LEMPAFIATKVSQYSCQRKTTLNYYNKKFTDAFEVMAENYE	179
XP_036017403.1	GRHQLVVNRNSSPSPVPGSQNPAPAVKKISQYACQRRTTLNNYNQLFTDALDILAENDE	180
	::*: : * :*. :*** ..*:***:*****:*****:***:*** *	
XM_026799623.1	FKENEIFCLEFLRAASLLKSLPFSVTRMKDIQGLPCVGDQVRDIEEEIIIEEGESSRVNEV	239
XP_036017403.1	LRENEGSCLAFLMRASSVLKSLPFPITSMKDTEGIPCLGDKVKSIIIEGIIEDGESSEAKAV	240
	:*** ** *:***:***** :* *** :***:***:***:*** .: *	
XM_026799623.1	LNDERYKAFKQFTSVFGVGVTSEKWYRMLRTVEEVKADKTLKLSMQKAGLLYYEDLV	299
XP_036017403.1	LNDERYKSFKLFITSVFGVGLKTAEKWFRMGFRTLSKIQSDKSLRFTQMOKAGFLYYEDLV	300
	*****:*** *****:***:***:***:***:***:***:***:*****:*****	
XM_026799623.1	SCVSKAEDAVSLIVKNTVCTFLPDALVTITGGFRRGKNIGHIDFLITNPGPRED--DE	357
XP_036017403.1	SCVNRPEAEAVSMLVKEAVVTFLPDALVTMTGGFRRGKMTGHDVDFLITSPEATEDEEQQ	360
	.: ***::***:*** *****:*****:***:***,* ** : :	
XM_026799623.1	LLHKVIDLWKKQGLLLYCDIIESTFVKEQLPSRKVDAMDHFQKCFAILKLYQPRVDNSTC	417
XP_036017403.1	LLHKVTDFWKQQGLLLYCDILESTFEKFKQPSRKVDALDHFQKCFILKLDHGRVHSEK-	419
	***** *:***:*****:*** * : *****:***** *** : *....	
XM_026799623.1	NTSEQLEMAEVKDWAIRVDLVTIPFEQYPYALLGWTGSRQFGRDLRYYAAHERKMILDN	477
XP_036017403.1	-----SGQQEGKGWKAIRVDLVMCPYDRRAFALLGWTGSR-FERDLRYYAHERKMMLDN	473
	* *.*****: ***: :*****:***** * *****:*****:***	
XM_026799623.1	HGLYDRRKRIFLKAGSEEEIFAHGLDYIEPWERNA 513	
XP_036017403.1	HALYDRTKRVFLEAESEEEIFAHGLDYIEPWERNA 509	
	*.**** ***:***:*** *****:*****:*****	

Mutations performed R335L-K337G

The only cysteine residues in the construct are two buried cysteines depicted (Cys155, Cys404) and Cys302 (yellow) that serves as attachment point for the linker.

> ThetaDtd+

MDRFKAPAVISQRKRQKGLHSPKLSASYEIKFSNFVIFIMQRKMGLTRRM	50
FLMELGRRKGFRVESELSDSVTHIVAENNSYLEVLDWLKGQAVGDSSRFE	100
LLDISWFTAAMEAGRVDSEVKYRLMEQSPLNMPALEMPAFIATKVS	150
QYSCQRKTTLNNYNKKFTDAFEVMAENYEFKENEIFALEFLRAASLLKSL	200
PFSVTRMKDIQGLPAVGDQVRDIIIEEIEEGESSRVNEVLNDERYKAFKQ	250
FTSFGVGVKTSEKWYRMLRTVEEVKADKTLKLSKMHQAGLILYYEDLVS	300
CVSKAEADAVSLIVKNTVATFLPDALVTITGGFRLGGNIGHDIDFLITNP	350
GPREDDELLHKVIDLWKKQGLLLYADIESTFVKEQLPSRKVDAMDHFQK	400
CFAILKLYQPRVDNSTANTSEQLEMAEVKDWKAIRVDLVITPFEQYPYAL	450
LGWTGSRQFGRDLRRYAAHERKMILDNHGLYDRRKRIFLKAGSEEIFAH	500
LGLDYVEPWERNA	

Improved DNA:

ATGGACCCTTCAAAGCTCCGGCTGTTATCTCTACCGTAAACGTCAAGAA	50
AGGTCTGACTCTCCGAAACTGTCTGCTTCTACGAAATCAAATTCTTA	100
ACTTCGTTATCTCATCATGCAGCGTAAAATGGGCTGACCCGTCGTATG	150
TTCCTGATGGAACTGGGTCGTCGTAAAGGTTCCGTGTTGAATCTGAAC	200
GTCTGACTCTGTTACCCACATCGTGCTGAAAACAACCTTACCTGGAAG	250
TTCTGGACTGGCTGAAAGGTCAAGGCTGTTGGTACTCTCTGTTGAA	300
CTGCTGGACATCTTGGTTACCGCTGCTATGGAAGCTGGTCGTCCGGT	350
TGACTCTGAAGTTAAATACCGTCTGATGGAACAGTCTCAGTCTGCCGC	400
TGAACATGCCGGCTCTGAAATGCCGGCTTCATCGTACCAAAGTTCT	450
CAGTACTCTTGCCAGCGTAAAACCACCTGAACAACTACAACAAAAATT	500
CACCGACGCTTCGAAGTTATGGCTGAAAACTACGAATTCAAAGAAAAG	550
AAATCTCGCTCTGGAATTCTCGCTGCTGTTCTGCTGAAATCTCG	600
CCGTTCTCTGTTACCGTATGAAAGACATCCAGGGCTGCGCCGGCTGTTGG	650
TGACCAGGTTCGTGACATCATCGAAGAAATCATCGAAGAAGGTGAATCTT	700
CTCGTGTAAACGAAGTTCTGAACGACGAACGTTACAAAGCTTCAAACAG	750
TTCACCTCTGTTTCGGTGTGTTAAAACCTCTGAAAATGGTACCG	800
TATGGGTCTCGGTACCGTTGAAGAAGTTAAAGCTGACAAAACCTGAAAC	850
TGTCTAAAATCGAGAAAGCTGGCTGCTGTACTACGAAGACCTGGTTCT	900
TGCGTTCTAAAGCTGAAGCTGACGCTGTTCTGATGTTAAAACAC	950
CGTTGCTACCTTCTGCCGGACGCTGGTTACCATCACCGGGTGGTTCC	1000
GTCTGGGTGGTAAACATCGGTACGACATCGACTTCTGATCACCAACCCG	1050
GGTCCCGGTGAAGACGACGAACGCTGCACAAAGTTATGACCTGTGGAA	1100
AAAACAGGGTCTGCTGTACGCTACGACATCATCGAATCTACCTCGTTA	1150
AAGAACAGCTGCCGTCTGTAAGTTGACGCTATGGACCACCTCCAGAAA	1200
TGCTCGCTATCCTGAAACTGTACCGCCGCTGTTGACAACCTACCGC	1250
TAACACCTCTGAACAGCTGGAAATGGCTGAAGTTAAAGACTGGAAAGCTA	1300
TCCGTGTTGACCTGGTTATCACCCGTTCGAACAGTACCGTACGCTCTG	1350
CTGGGTTGGACCGGTTCTCGTCAGTTGGCTGACCTGCGTCGTTACGC	1400
TGCTCACGAACGTAAAATGATCCTGGACAACCAACGGTCTGTACGACCGTC	1450
GTAAACGTATCTCTGAAAGCTGGTTCTGAAGAAGAAATCTCGCTCAC	1500
CTGGGCTGGACTACGTTGAACCGTGGGAACGTAACGCT	

> ThetaDtD+

TccggcgttagaggatcgagatcgatccgcgaaattaatacgactcactatagggattgtgacggataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggatgaaagaaccgctgctgAAattcgAACGCCAGCACATGGACAGCCCAGATCTGGGTGAAACCTGTACTTCCAG

ATGGACCGTTCAAAGCTCCGGCTTATCTCTAGCGAACGTCAGAAAGGTCTGCACTCTCGAAACTGTCTGCTTACGAAATCAAATTCTAATTCGTTATCTCATCATGCAGCGTAAAATGGTCTGACCGCTCGATGTCCTGATGGAACGGGTCGTCGAAAGGTTCCGTGTTGAATCTGAACTGTCTGACTCTGTTACCCACATCGTTGCTGAAAACAACCTTACCTGGAAGTTCTGGACTGGCTGAAAGGTCAAGCTGTTGGTACTCTCTCGTTGAACTGCTGGACATCTTGGTTACCGCTGCTATGGAAGCTGGTCGTCGTTGACTCTGAAACTGCCGCTCTGAAATGCCGGCTTCTGCTACCAAAGTTCTCAGTACTCTGCCAGCGTAAAACCACCCGTAACAACAAAAATTACCGACGCTTCAAGTTATGCTGAAAACGAAATTCTCGCTCTGGAATTCTCGTGTGCTCTGCTGAAATCTGCGCTCTGTTACCCGTATGAAAGACATCCAGGGTCTGCCGGCTGTTGGTACCGAGGTTCTGACATCATCGAAGAAATCATCGAAGAAGGTGAACTCTCTCGTGTAAACGAAGTTCTGAACGACGAACGTTACAAAGCTTCAACAGTTCACCTCTGTTTCGGTGTGTTAAAACCTCTGAAAAATGGTACCGTATGGTCTGCGTACCGTTGAAAGAAGTTAAAGCTGACAAAACCCGTAACACTGTCTAAATGCAAGAAAGCTGGTCTGCTGTTCTGTTCTGTTGTTACCATCACCGTGTTCTGGGTGTTACATCGGTACGACATCGACTCCTGATCACCACCCGGTCCCGTGAAGACGACGAACGTCGACAAAGTTATCGACCTGTGAAAAAACAGGGTCTGCTGTCAGCTGACATCATCGAATCTACCTCGTTAAAGAACAGCTGCCGTCTCGTAAAGTTGACGCTATGGACCACTTCCAGAAATGCTCGCTATCCTGAACTGTGTTGACAACACTTACCGCTAACACCTCTGAACAGCTGAAATGGCTGAAAGACTGGAAAGCTATCCGTTGACCTGGTTATCACCCGTTGAAACAGTACCCGTAACGCTCTGCTGGTTGGACCGGTTCTCGTAGTCGGTACGCTGACCTGCGTCGTTACCGCTGCTCACCGTCTGGACTACGTTGAAACCGTGGGAAACGTAACGCTtag

> ThetaDtD+STN

TccggcgttagaggatcgagatcgatctcgatcccgcaaattaatacgactcactatagggaatttgtgagcgataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggtatgaaaggaaaccgctgctgctAattcgAACGCCAGCACATGGACAGCCCAGATCTGGGTGAAACCTGTACTTCCAG

ATGGAAGAAAAGTTGTAACCTGAAACCGAACATGGAATCTGTTACGTTACCGCTCGTGGAGCTTCTGAAGCTCGTCAGATCCAGACCAAAACGGTGGTGTACCATCTCTGAAGCTATCGTTGGTGACGAAACCGGCGTGTAAACTGACCCGTGGGTAA
CACGCTGGTTCTATCAAAGAAGGTCAAGTTGTTAAATCGAAAACGCTTGGACCACCGCTTCAAAGGTCAAGGTCAGGTCAGCTGAACGCTGGTCTAAAACCAAAATCGCTGAAGCTCTGAAGACGGTTCCCGGAATCTTCTCAGATCCC
GAAAACACCCCCGACCGCTCCGCAGCAGATGCGTGGTGGTGGTGTGGTTCCGTGGTGGTGTGCTGTTACGGTCGTGTCAGGAAAACGAAGAAGGTGAAGAAGAA

> ThetaDtD+STC

TccggcgttagaggatcgagatcgatctcgatcccgcaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaactttagaaggagatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggtatgaaaaaaccgctgctgctAattcgAACGCCAGCACATGGACAGCCCAGATCTGGGTGAAACCTGTACTTCCAG

ATGGACCGTTCAAAGCTCCGCTTATCTCTAGCGTAAACGTCAAGAAAGGTCTGCACTCTCGAAACTGTCTGCTTCTACGAAATCAAATTCTAATTCGTTATCTCATCATGCAGCGTAAAATGGTCTGACCGCTGTATGGAACGGTCGTCGTAAGGTTCCGTGTTGAATCTGAACGTCTGACTCTGTTACCCACATCGTTGCTAAAACAACACTTACCTGGAAGTTCTGGACTGGCTGAAAGGTCAAGGCTGTTGGTACTCTCTCGTTCGAACTGCTGGACATCTCTGGTTACCGCTGCTATGGAAGCTGGTCGTCGTTGACTCTGAAAGCTCAGTCTGCGCTGAAACATGCCGGCTCTGAAATGCCGGCTTCATCGCTACCAAAGTTCTCAGTACTCTGCCAGCGTAAAACCACCCGTAACAACAAAAATTACCGACGCTTCGAAGTTATGCTGAAAACATCGAATTCAAAGAAAAGAAATCTCGCTCTGGAATTCTCGTGTGCTCTGCTGAAATCTGCCGTTCTGTTACCGTATGAAAGACATCCAGGGTCTGCCGGCTGTTGGTACCGAGGTTCTGACATCATCGAAGAAATCATCGAAGAAGGTGAACTCTCTCGTGTAAACGAAGTTCTGAACGACGAACGTTACAAAGCTTCAAACAGTTACCTCTGTTTCGGTGTGTTAAAACCTCTGAAAAATGGTACCGTATGGTCTGCGTACCGTTGAAAGAAGTTAAAGCTGACAAAACCCGTAACACTGTCTAAATGCGAGAAAGCTGGTCTGCTGACTACGAAGACCTGGTTCTGCGTTCTAAAGCTGAAGCTGACGCTTCTGATCGTTAAAACACCCTGCTACCTCCTGCCGGACGCTCGGTTACCATCACCGTGTTCCGTCGGGTGTAACATCGGTACGACATCGACTCCTGATCACCACCCGGTCCGCGTGAAGACGACGAACGTGCAAAAGTTATCGACCTGTGAAAAAACAGGGTCTGCTGCTGACATCATCGAATCTACCTCGTTAAAGAACAGCTGCCGTCGTAAGGTTACGCTATGGACCACTCCAGAAATGCTCGCTATCCTGAAACTGTACCGCTGTTGACAACACTCACCGCTGAAACAGCTGGAAATGGCTGAGTTAAAGACTGGAAAGCTATCCGTTGACCTGGTTATCACCCGTTGAAACAGTACCGCTCGCTGGTTGGACCGGTTCTCGTAGTCGGTCGTGACCTCGTCGTTACCGCTGGGAAACGTAACGCT

ATGGAAGAAAAGTTGTAACCTGAAACCGAACATGGAATCTGTTACGGTTCGTTCTGGAAAGCTTCTGAAGCTCGTCAGATCCAGACCAAAACGGTTCGTAACCATCTCTGAAGCTATCGTTGGTGACGAAACCGGTCGTAAACTGACCCGTGGGTAA
CACGCTGGTTCTATCAAAGAAGGTCAAGTTGTTAAATCGAAAACGCTTGGACCACCGCTTCAAAGGTCAAGGTCAGGTCAGCTGAACGCTGGTTCTAAAACCAAAATCGCTGAAGCTCTGAAGACGGTTCCCGGAATCTTCTCAGATCCC
GAAAACACCCCCGACCGCTCCGCAGCAGATGCGTGGTGGTGGTCGTGGTTCCGTGGTGGTCGTACGGTCGTGGTGGTCGTCAAGGAAAACGAAGAAGGTGAAGAAGAATag

> ThetaDtD+SN

TccggcgttagaggatcgagatcgatctcgatcccgcgaaattaatacgaactcaactatagggaaattgtgagcgataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattctctggtgccacgcgt
tctggtatgaaagaaaccgctgctgctAattcgaaacgccagcacatggacagccagatctgggtGAAAACCTGTACTTCCAG

GCTACCGTTAATTCAAATACAAGGTGAAGAAAAAGAACATCTCTAAATCAAAAAGTTGGCGTGGTAAATGATCTCTTACCGACGAAGGTGGTGGTAAACCGGTGCTGGTCTGAAAAAGACGCTCCGAAAGAACTGCTGCAGATGCTG
GAAAAACAGAAAAA

ATGGACGTTCAAAGCTCCGGCTGTTATCTCTAGCGTAAACGTCAAGAAAGGTCTGCACTCTCCGAAACTGTCTGCTTCTACGAAATCAAATTCTCTAACTTCGTTATCTTCATCATGCAGCGTAAATGGGTCTGACCCGTCTATGTTCTGATGGAACGGTCTGCGTCCGAAAGGTTCCGTGTTGAATCTGAACGTCTGACTCTGTTACCCACATCGTTGCTGAAAACAACACTCTTACCTGGAAAGTTCTGGACTGGCTGAAAGGTCAAGGCTGTTGGTACTCTCTCGTTCACTGCTGGACATCTTGTTCACCGCTGCTATGGAAGCTGGTCTCGGACTCTGACTCTGCTGCTAACAGTCTGAAACATGCCGGCTCTGGAAATGCCGGCTTCATCGCTACCAAAGTTCTAGTACTCTGCCAGCGTAAAACCACCCCTGAACAACTACAACAAAAATTACCGACGCTTCGAAGTTATGGTCTGAAAGTAAATACCGTCTGATGGAACAGTCTCAGTCTGCCGCTGAACATGCCGGCTCTGGAAATGCCGGCTTCATCGCTACCAAAGTTCTAGTACTCTGCCAGCGTAAAACCACCCCTGAACAACTACAACAAAAATTACCGACGCTTCGAAGTTATGCTGAAAACATCGAATTCAAAGAAAACGAAATCTCGCTCTGGAAATTCTCGCTGCTGCTGCTGAAATCTCGCCGTTCTGTTACCGTATGAAAGACATCCAGGGTCTGCCGGCTGTTGGTACCGTACATCGAAGAAATCATCGAAGAAAGGTGAACTCTCTCGTGTAAACGAAGTTCTGAACGACGAACGTTAACAGCTTCAAACAGTTCACCTCTGTTTCGGTGTGTTAAAACCTCTGAAAATGGTACCGTATGGGTCTGCGTACCGTTGAAGAAGTTAAAGCTGACAAAACCCCTGAAACTGTCTAAATGCAGAAAGCTGGTCTGACTACGAAGACCTGGTTCTGCGTTCTAAAGCTGAAGCTGACGCTGTTCTGATCGTAAACACCGTTGCTACCTTCTGCCGACGCTCTGGTTACCATCACCGTGGTTCCGCTGGGTGGTAACATCGGTACGACATCGACTTCGTACCAACCCGGTCCGCGTGAAGACGACGAACGTGCTGCACAAAGTTATCGACCTGTGGAAAAAAACAGGGTCTGCTGCTGACATCATCGAATCTACCTCGTAAAGAACAGCTGCCGCTCGTAAAGTTGACGCTATGGACCACTTCCAGAAATGCTCGTATCCGAACTGTTACCGCGTGTGTTGACAACCTACCGCTAACACCTCTGAACAGCTGGAAATGGCTGAAGTTAAAGACTGGAAAGCTATCCGTTGACCTGGTTATCACCCGTTCGAACAGTACCCGTAACGCTCTGCTGGGTGGACCGGTTCTCGTCAGTCGGTGTGACCTCGCTCGTTACGCTGCTCACGACGCTGCTGGGACTACGTTGAACCGTGGGAACGTAACGCTtag

> ThetaDtD+SC

TccggcgttagaggatcgagatcgatctcgatcccgcgaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattctctggctggccacgcgt
tctggtatgaaaagaaaccgcgtcgtaattcgaaacgccagcacatggacagccagatctgggtGAAAACCTGTACTCCAG

GCTACCGTTAAATTCAAATACAAGGTGAAGAAAAAGAAGTTGACATCTCTAAAATCAAAAAGTTGGCGTGTGGTAAAATGATCTCTTACACGACGAAGGTGGTGGTAAAACCGGTCGTGGTCTGTTCTGAAAAAGACGCTCCGAAAGAACTGCTGCAGATGCTG
GAAAAACAGAAAAAAGtag

Codon optimized protein sequences

> Pfu

MDRFKAPAVISQRKRQKGLHSPKLSASYEIKFSNFVIFIMQRKMLTRRM 50
FLMELGRRKGFRVESELSDSVTHIVAENNSYLEVLDWLKGQAVGDSSRFE 100
LLDISWFTAAMEAGRVDSEVKYRLMEQSQSLPLNMPALEMPAFIATKVS 150
QYSCQRKTLNNYNKKFTDAFEVMAENYEFKENEIFALEFLRAASLLKSL 200
PFSVTRMKDIQGLPAVGQVRDIIIEEIEEGESSRVNEVLNDERYKAFKQ 250
FTSVFGVGVKTSEKWYRMLRTVEEVKADKTLKLSKMQKAGLLYYEDLVS 300
CVSKAEADAVSLIVKNTVATFLPDALVTITGGFRLGGNIGHIDFLITNP 350
GPREDDELLHKVIDLWKKQGLLLYADIESTFVKEQLPSRKVDAMDHFQK 400
CFAILKLYOPRVDNSTANTSEOLEMAEVKDWKAIRVDLVITPFEQYPYAL 450

LGWTGSRQFGRDLRRYAAHERKMILDNHGLYDRRKRIFLKAGSEEEIFAH
LGLDYVEPWERNA

Improved DNA:

ATGGACCGTTCAAAGCTCCGGCTGTTATCTCTCAGCGAACGTCAAGAA 50
AGGTCTGCACTCTCGAAACTGTCTGCTTACGAAATCAAATTCTCTA 100
ACTTCGTTATCTCATCATGCAGCGAAAATGGGCTGACCCGTCGTATG 150
TTCCTGATGGAACTGGGTCGTCGTAAGGTTCCGTGTTGAATCTGAAC 200
GTCTGACTCTGTTACCCACATCGTGCTGAAAACAACCTTACCTGGAAG 250
TTCTGGACTGGCTGAAAGGTCAAGGCTGTTGGTACTCTCTCGTTGAA 300
CTGCTGGACATCTTGGTTCACCGCTGCTATGGAAGGCTGGTCGTCGGT 350
TGACTCTGAAGTTAAATACCGTCTGATGGAACAGTCTCAGTCTGCCGC 400
TGAACATGCCGGCTGGAAATGCCGGTTCATCGCTACCAAAGTTCT 450
CAGTACTCTTGCAGCGTAAAACCACCTGAACAACATAACAAAAAATT 500
CACCGACGCTTCGAAGTTATGGCTGAAAACATCGAATTCAAAGAAAAG 550
AAATCTCGCTCGGAATTCTCGTGCTGCTCTGCTGAAATCTCG 600
CCGTTCTCTGTTACCGTATGAAAGACATCCAGGGTCTGCCGGCTGTTGG 650
TGACCAGGTTCTGACATCATCGAAGAAATCATCGAAGAAGGTGAATCTT 700
CTCGTGTAAACGAAGTTCTGAACGACGAACGTTACAAAGCTTCAAACAG 750
TTCACCTCTGTTTCGGTGTGTTAAAACCTCTGAAAAATGGTACCG 800
TATGGGTCTGCGTACCGTTGAAGAAGTTAAAGCTGACAAAACCTGAAAC 850
TGTCTAAAATGCAGAAAGCTGGTCTGCTGTACTACGAAGACCTGGTTCT 900
TGCCTTCTAAAGCTGAAGCTGACGCTGTTCTGATGTTAAAACAC 950
CGTTGCTACCTCCCTGCCGGACGCTCGTTACCATCACCGGGTGGTTCC 1000
GTCTGGGTGGTAAACATCGGTACGACATCGACTCCTGATCACCAACCCG 1050
GGTCCCGGTGAAGACGACGAACGCTGTCACAAAGTTATGACCTGTGGAA 1100
AAAACAGGGTCTGCTGTCGCTGACATCATCGAATCTACCTCGTTA 1150
AAGAACAGCTGCCGTCTCGTAAAGTTGACGCTATGGACCACTCCAGAAA 1200
TGCTTCGCTATCCTGAAACTGTACCAAGCCGCGTGTGACAACCTACCGC 1250
TAACACCTCTGAACAGCTGAAATGGCTGAAGTTAAAGACTGGAAAGCTA 1300
TCCGTGTTGACCTGGTTATACCCCGTTGAAACAGTACCGTACGCTCTG 1350
CTGGGTTGGACCGGTTCTCGTCAGTTGGTCGTGACCTCGTCGTTACGC 1400
TGCTCACGAACGTAAAATGATCCTGGACAACCACGGTCTGTACGACCGTC 1450
GTAAACGTATCTCCTGAAAGCTGGTTCTGAGAAGAAAATCTCGCTCAC 1500
CTGGGTCTGGACTACGTTGAACCGTGGGAACGTAACGCT

> Taq (delta289)

SPKALEEAPWPPPEGAFVGFLSRKEPMWADLLALAAARGGRVHRAPEPY 50
KALRDLKEARGLLAKDLSVLALREGLGLPPGDDPMLLAYLLDPSNTTPEG 100
VARRYGEWTEEAGERAALSERLFANLWGRLEGEERLLWLYREVERPLSA 150
VLAHMEATGVRLDVAYLRLSLEVAEEIARLEAEVFRLAGHPFNLSRDQ 200
LERVLFDELGLPAIGKTEKTGKRSTSAAVLEALREAHPIVEKILQYRELT 250
KLKSTYIDPLPDLIHPRTRGLHTRFNQTATATGRLSSSDPNLQNIPVRTP 300
LGQRIRRAFIAEEGWLLVALDYSQIELRVLAHLSGDENLIRVFQEGRDIH 350
TETASWMFGVPREAVDPLMRRAAKTINFVLYGMSAHLRSQELAIPYEEA 400
QAFIERYFQSFPKVRAWIEKTLEEGRRGYVETLFGRRRYVPDLEARVKS 450
VREAAERMAFNMPVQGTAADLMKLAMVKLFPRLLEEMGARMLLQVHDELVL 500
EAPKERAEEAVARLAKEVMEGVYPLAVPLEVEVGIGEDWLSAKE

Improved DNA:

TCTCCGAAAGCTCTGGAAGAAGCTCCGTGGCCGCCGGAAAGGTGCTTT 50
CGTTGGTTTCGTTCTGTCGTAAGAACCGATGTGGGCTGACCTGCTGG 100

CTCTGGCTGCTCGTGGTGGTCGTGTTACCGTGCTCCGGAACCGTAC AAAGCTCTCGTGACTGAAAGAAGCTCGTGGTCTGCTGGCTAAAGACCT GTCTGTTCTGGCTCTGCCTGAAGGTCTGGGCTGCCGCCGGGTGACGACC CGATGCTGCTGGCTTACCTGCTGGACCCGCTAACACCACCCCGAAGGT GTTGCTCGTACGGTGGTAATGGACCGAAGAAGCTGGTGAACGTGC TGCTCTGCTGAACGTCTGCTAACCTGTGGGCTGCTGGAAAGGTG AAGAACGTCTGCTGTGGCTGACCGTGAAGTTGAACGTCCGCTGTGCT GTTCTGGCTCACATGGAAGCTACCGTGGCTCTGGACGTTGCTTACCT GCGTCTGCTGTCTGGAAAGTTGAAGAAATCGCTGCTGGAAAGCTG AAGTTTCCGTCGGCTGGCACCGTTAACCTGAACTCTCGTGACCAAG GTGAAGCTACCCGATCGTTAAAAATCCTGCAGTACCGTGAACGTGACC GTCTGTCTCTCTGACCCGAACCTGCAGAACATCCGGTTGCTACCCCG CTGGGTAGCGTATCCGTCGTCTTCATCGCTGAAGAAGGTTGGCTGCT GGTTGCTCTGGACTACTCTCAGATCGAAGTGCCTGTTCTGGCTCACCTGT CTGGTGACGAAAACCTGATCCGTTGGATGTTGGCTCGCGTGAAGCTGTTGACCC ACCGAAACGCTCTGGATGTTGGCTCGCGTGAAGCTGTTGACCC GCTGATGCGTCGTGCTGCTAAAACCATCAACTTCGGTGTGTTGACCGTA TGTCTGCTACCGTCTGCTCAGGAACGGCTATCCCCTGACGAAAGACT CAGGCTTCATCGAACGTTACTTCCAGTCTTCCGGAAAGTTCGTGCTTG GATCGAAAAAACCTGGAAGAAGGTCGTCGTGGTACGGTAAACCC TGTTCGGTGTCGTCGTTACGTTCCGGACCTGGAAGCTCGTGTAAATCT GTTCGTGAAGCTGCTGAACGTATGGTTAACATGCCGGTCAGGGTAC CGCTGCTGACCTGATGAAACTGGCTATGGTTAACGGTCTCCCGGTCTGG AAGAAATGGGTGCTCGTATGCTGCTGCAGGTTACGACGAACGGTTCTG GAAGCTCGAAAGAACGTGCTGAAGCTGTTGCTCGTGGCTAAAGAAGT TATGGAAGGTGTTACCGCTGGCTTCCGCTGGAAGTTGAAGTTGGTA TCGGTGAAGACTGGCTGCTGCTAAAGAA	150 200 250 300 350 400 450 500 550 600 750 900 950 1000 1050 1100 1150 1200 1250 1300 1350 1400 1450 1500 1550 1600	650 CGAAAAAACCGTAAACGTTTACCTCTGCTGTTCTGGAAGCTCTGC 800 TACCGGTCGTCTGCACACCGTTAACCAACCAGACCGTACCGCTACCGGTC	700 850
> Sso7d ATVKFKYKGEKEVDISKIKKVWRVGKMSFTYDEGGGKTGRAVSEKDA PKELLQMLEKQKK	50		
Improved DNA: GCTACCGTTAAATTCAAATACAAAGGTGAAGAAAAAGAAGTTGACATCTC TAAATCAAAAAGTTGGCGTGTGGTAAATGATCTCTTACCTACG ACGAAGGTGGTGTAAACCGGTCGTGGTCTGTTCTGAAAAAGACGCT CCGAAAGAACTGCTGCAGATGCTGGAAAAACAGAAAAAA	50 100 150		
> ThetaSsoT MEEKVGNLKPMEVNVTVRVLEASEARQIQTNGVRTISEAIVGDETGR VKLTLWGKHAGSIKEGQVVKIENAWTAFKGQVQLNAGSKTKIAEASEDG FPESSQIPENTPTAPQQMRGGGRGFRGGGRRYGRGGRRQENEEGEEE	50 100		
Improved DNA: ATGGAAGAAAAAGTTGGTACCTGAAACCGAACATGGAATCTGTTAACGT TACCGTTCGTGTGGAAGCTCTGTAAGCTCGTCAGATCCAGACCAAAA ACGGTGTTCGTACCATCTCTGAAAGCTATCGTGGTGACGAAACCGGTGCT GTTAAACTGACCCGTGGGTAACACGCGTGGTTATCAAAGAAGGTCA GGTTGTTAAAATCGAAACCGCTGGACCCGCTTCAAAGGTCAAGGTTC AGCTGAACGCTGGTCTAAAACCAAAATCGCTGAAGCTGAAAGACGGT	50 100 150 200 250 300		

TTCCCGGAATCTTCAGATCCGGAAAACACCCGACCGCTCCGCAGCA
GATGCGTGGTGGTCGTGGTTCCGTGGTGGTCGTACGGTC
GTCGTGGTGGTCGTCAAGGAAAACGAAGAAGGTGAAGAAGAA

350
400

> Theta43 Expression construct

TccggcgtagaggatcgagatctcgatcccgaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaacttaagaaggatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggatgaaagaaaccgctgctgctAattcgaacgccagcacatggacagccagatctgggtaccgacgacgacgacaag

2) ThetaPfu+S

TccggcgtagaggatcgagatctcgatcccgaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaacttaagaaggatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggatgaaagaaaccgctgctgctAattcgaacgccagcacatggacagccagatctgggtGAAAACCTGTACTCCAG

ATGGACCCTTCAAAGCTCCGGCTGTTATCTCAGCGTAACGTCAGAAAGGTCTGCACTCTCGAAACTGTCTGCTTACGAAATCAAATTCTAACTTCGTTATCTTCATCATGCAGCGTAAATGGGTCTGACCCGTCGTATGGAACTGGTCGTCGT
AAAGGTTTCCGTGTTGAACTGTAACGACTGTTACCCACATCGTTGCTGAAAACAACACTTACCTGGAAGTTCTGGACTGGCTGAAAGGTCAGGCTGGTGAACATCTTCTCGTTCACTGCTGAACTGCTGGACATCTTGGTTACCGCTGCTATGGAAAGCTGGTCGTC
GTTGACTCTGAAGTTAAATACCGTCTGATGGAACAGTCTCAGTCTGCCGCTGAAACATGCCGGCTCTGAAATGCCGGTTTCTCGCTACCAAAGTTCTCAGTACTCTTGCCAGCGTAAACACCACCTGAACAACATAACAAAAAAATTCCAGCAGCTTCGAAGTTATG
GCTGAAAACACTACGAATTCAAAGAAAACGAAATCTCGCTCTGGAATTCCCTCGTGCTGCTGAAATCTCGCCGTTCTGTTACCGTATGAAAGACATCCAGGGCTGCCGGCTGGTGAACAGGTTCTGACATCATCGAAGAAATCATCGAAGAAGGTGAA
TCTTCTGTTAACGAAGTTCTGAACGACGTTACAAAGCTTCAAACAGTTACCTCTGTTTCGGTGTGTTAAACCTCTGAAAATGGTACCGTATGGTCTGCTGTTACCGTACCTGTTACCGTATGAAAGACATCCAGGGCTGCCGGCTGGTGAACAGTCTAAATGCAAGAAAGCT
GGTCTGCTGACTACGAAGACCTGGTTCTGCTTCTAAAGCTGAAGCTGACGCTGTTCTGATGTTAAACACCCTGCTGCTGCTGACATCATCGAATCTACCTCGTTAAAGAACAGCTGCCGCTCGTAAAGTTGACGCTATGGACCACCTCCAGAAATGCTGCTATCTGAA
AACCCGGTCCCGCTGAAGACGACGAACCTGTCGACAAAGTTATCGACCTGTTAAACAGCTGGAAATGGCTGAAGTTAAAGACTGGAAAGCTATCCGTGTTGACCTGGTTATACCCGTTGAAACAGTACCCGTAACGCTGCTGGTGGACCGGTTCTGTCAGTCGGTGTGACCTGCGT
CTGTTACCGCCGCTGTTGACAACACTCACCGCTAACACCTCTGAAACAGCTGGAAATGGCTGAAGTTAAAGACTGGAAAGCTATCCGTGTTGACCTGGTTATACCCGTTGAAACAGTACCCGTAACGCTGCTGGTGGACCGGTTCTGTCAGTCGGTGTGACCTGCGT
CGTTACGCTGCTACGAACGTAACGATCTGGACAACCACGGTCTGACGACCGTCGTAACGTATCTCGTAAAGCTGGTTCTGAAAGAAATCTCGCTCACCTGGTCTGGACTACGTTGAACCGTGGGAAACGTAACGCT

GCTACCGTTAAATTCAAATACAAAGGTGAAGAAAAAGAAGTTGACATCTAAATCAAACAGTTGGCGTGTGGTAAATGATCTTTCACCTACGACGAAGGTGGTAAACCGGTCGTGGCTGTTCTGAAAGAAAGACGCTCCGAAAGAAACTGCTGCAGATGCTG
GAAAAACAGAAAAAAAtag

3) ThetaTaq+S

TccggcgtagaggatcgagatctcgatcccgaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaacttaagaaggatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggatgaaagaaaccgctgctgctAattcgaacgccagcacatggacagccagatctgggtGAAAACCTGTACTCCAG

GCTACCGTTAAATTCAAATACAAAGGTGAAGAAAAAGAAGTTGACATCTAAATCAAACAGTTGGCGTGTGGTAAATGATCTTTCACCTACGACGAAGGTGGTAAACCGGTCGTGGCTGTTCTGAAAGAAAGACGCTCCGAAAGAAACTGCTGCAGATGCTG
GAAAAACAGAAAAAA

TCTCCGAAAGCTCTGGAAGAAGCTCCGTGGCCGCCGGAAAGGTGCTTCGTTGTTCTGCTCGTAAAGAACCGATGTGGCTGACCTGCTGGCTCTGGCTGCTCGTGGTGGCTGTTACCGTACCGTACCGTAAACACCACCCGGAAAGGTGGCTGCTCGTGGTAATGGACCGAAGAAGCTGGTAACG
GCTCGTGGCTGGCTAAAGACCTGTTCTGGCTCTGCGTAAGGTCTGGCTGCCGGGTGACGACCCGATGCTGCTGGCTTACCTGCTGGACCCGTTAACACCACCCGGAAAGGTGGCTGCTCGTGGTAATGGACCGAAGAAGCTGGTAACG
GCTGCTCTGCTGAACGCTGTTCTGCTAACCTGTTGGCTGCTGGTACCGTGAAGTTGAACGCTCCGCTGCTGCTGGCTCACATGGAAGCTACCGTGGCTGCTGGACCGTCTGCTGCTCTGGAAAG
GCTGAAGAAATCGCTCGTGGCTGGCTGGTACCGTGAAGTTCCGCTGGCTGGTACCGTCAACCTGAACTCTCGTGGCTGACCGAGCTGGAAACGTTCTGCTGGCTGCTGGTGGCTGCTGGTGGCTGCTGGTGGCTGCTGCTCTGGAAAGCT
CTGCGTGAAGCTACCCGATCGTTGAAAAACCTCTGCTGGCTGGTACCGTGAACGACAAACTGAAATCTACCTACATCGACCCGCTGCCGGACCTGATCCACCCCGCTACCGTCTGCTGACACCCGTTCAACAGACCGCTACCGTGGCTGCTGCTCTGGAAAGCT
AACCTGCGAAGACATCCGGTCTGGTACCCCGCTGGCTGGCTGGCTGGCTGGTACCGTGAACGACAAACTGAAATCTACCTACATCGACCCGCTGCCGGACCTGATCCACCCCGCTACCGTCTGCTGACACCCGTTCAACAGACCGCTACCGTGGCTGCTGCTCTGGAAAGCT
ATCCACACCGAAACCGCTTCTGGATGTTGGTCTGGCTGGTACCGTGAAGCTGTTGACCCGCTGATGCGTGTGCTGCTAAACACCATCAACTCGGTGTTCTGACGGTATGCTGCTCACCGTCTGCTGAGGAACCTGGCTACCCGTAACGCTCAGGCTTCAAGGAAAGCTCAGGCTTCA
TACTTCCAGTCTTCCGAAAGTTGCTGCTGGATCGAAAAACCGTGGAAAGAAGGTGCTGCTGGTACCGTGGTAAACCGTGGTCTGCTGCTGGTACCGTCTGCTGAGGAACCTGGCTACCCGTAACGCTCAGGCTTCAAGGAAAGCTGCTGTTCAACATGCCGGTT
CAGGGTACCGCTGCTGACCTGATGAAACTGGCTATGGTAAACTGGTCCCGCTGTAAGGAAATGGGTGCTGCTGATGCTGCTGAGGTTCACGACGAACCTGGTCTGGAAAGAAGCTGCTGTTAAATCTGCTGAGGCTGCTGAAACGTTGCTGAGCTGCTGCTGGCTAAAGAAGTTATGGAAGGTGTTAC
CCGCTGGCTGTTCCGCTGGAAGTTGAGGTTGCTGAGGTTGCTGCTAAAGAAAtag

4) Theta+PfUTPase

> PfUTPase

```
MLHHVKLIYATKSRKLVGKKIVLAIPGSIAAVECVKLARELIRHGAEVHA      50
VMSEAATKIIHPYAMEFATGNPVITEITGFIEHVELAGEHENKADLILVC     100
PATANTISKIACGIDDTPVTTVTTAAPHIPIMIAPAMHETMYRHPIVRE     150
NIERLKKLGVEFIGPRIEGKAKVASIDEIVYRVIKKLHKKTLEGKRVLV     200
TAGATREYIDPIRFITNASSGKMGVALAEEADFRGAEVTLIRTKGSVKSF     250
VENQIEVETVEEMLSAIENELRSKKYDVVIMAAVSDFRPKIKAEGKIKS     300
DRSITIELVPNPKIIDRIKEIQPNVFLVGFAETSKEKLIEEGKRQIERA     350
KADLVVGNLTLEAFGSEENQVVLIGRDFTKELPKMKKRELAERIWDEIEKL
LS
```

Improved DNA:

```
ATGCTGCACCACGTTAAACTGATCTACGCTACCAAATCTGTAACGGT      50
TGGTAAAAAAATCGTCTGGCTATCCGGGTTCTATCGCTGCTGTTGAAT    100
GCGTTAAACTGGCTCGTGAAGTGTACCGTCACGGTCTGAAGTTACGCT    150
GTTATGTCTGAAGCTGCTACCAAAATCATCCACCCGTACGCTATGGAATT  200
CGCTACCGTAACCCGGTTATCACCGAAATCACCGGTTATCGAACACGG   250
TTGAACTGGCTGGTGAACACGAAAACAGCTGACCTGATCCTGGTTGC    300
CCGGCTACCGCTAACACCATCTCTAAATCGCTGCGGTATCGACGACAC  350
CCCGGTTACCACCGTTTACACCGCTTCCCGACATCCCAGATCATGA    400
TCGCTCCGGCTATGCACGAAACCATGTACCGTCACCCGATCGTCGTGAA  450
AACATCGAACGCTGAAAAAAACTGGGTGTTGAATTATCGGTCGCGTAT   500
CGAAGAAGGTAAGCTAAAGTTGCTTATCGACGAAATCGTTACCGTG    550
TTATCAAAAAACTGCACAAAAAAACCGTGAAGGTAACGTGTTCTGGTT  600
ACCGCTGGTGTACCGTGAATAACATCGACCCGATCCGTTATCACCAA   650
CGCTTCTTCTGGTAAAATGGGTGTTCTGGCTGAAGAAGCTGACTTCC  700
GTGGTCTGAAGTTACCGTACCGTACCAAAAGGTTCTGTTAAATCTTC  750
GTTGAAAACAGATCGAACGTTGAAACCGTTGAAGAAATGCTGCTGCTAT 800
CGAAAACGAACTCGCTTCTAAAAATACGACGTTTATCGGCTGCTG    850
CTGTTCTGACTCCGTGAAAATCAAAGCTGAAGGTAACGTTAAATCT   900
GACCGTTCTATCACCATCGAACACTGGTCCGAACCCGAAAATCATCGACCG 950
TATCAAAGAAATCCAGCCGAACGTTTCTGGTTGGTTCAAAGCTGAAA 1000
CCTCTAAAGAAAAACTGATCGAAGAAGGTAACGTCAGATCGAACGTC  1050
AAAGCTGACCTGGTTGGTAACACCCCTGGAAGCTTCGGTTCTGAAAGA 1100
AAACCAAGGTTGTTCTGATCGGTCGTGACTTCACCAAAGAACTGCCGAAA 1150
TGAAAAAAACGTGAACGTTGCTGAACGTATCTGGGACGAAATCGAAAAACTG 1200
CTGTCT
```

> Theta+PfUTPase

TccggcgtagaggatcgagatcgatctcgatcccgcaaattaatacgactcactatagggaaattgtgagcgataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattttctggctggccacgcggttctggatgaaagaaaccgcgtcgtaattcgaaacgccagcacatggacagccagatctgggtaccgacgacgacgacaag

```
ATGCTGCACCACGTTAAACTGATCTACGCTACCAAATCTGTAACGGTAAAAAAATCGTCTGGCTATCCGGGTTCTATCGCTGCTGTTGAATCGTTAAACTGGCTCGTGAAGTTACCGTCACGGTCTGAAGTTACCGCTGTTATGTCTGAAGCTGCTACCAAATCATCCACCGTACGCTATGGAATTGCTACCGTACCCGGTTATCACCAGAAATCACCGTTATCGAACACGTTGACACGAAAACAAAGCTGACCTGATCCTGGTTGCCCGCTACCGCTAACACCCTCTAAATCGCTTGGTCTACGACGACACCCGGTTACCCGGTTACCCGGCTTCCCGACATCCGATCATGATCGCTCCGGCTATGCACGAAACCATGTACCGTCACCCGATCGTGAAGGAAACATCGAACGTCGAAAAAAACTGGGTGTTGAATTATCGGTCCGGTATCGAAGAAGGTAAGCTAAAGTTGCTATCGACGAAATCGTTACCGTGTGTTATCAAAACCCCTGGAAGGTAACGTTGTTACCGCTGGTCTACCGTGAATACATCGACCCGATCCGTTATCACCACGCTTCTGGTAAATGGGTGTTCTGGCTGAAGAAGCTGACCTCCGGTCTGAAGAAGCTGACCTCCGGTCTGAAGGTTACCGTACCCCTGTAACAGGTTCTGTTAAATCTTCTGTTGAAACCCAGATCGAACGTTGAAAGAAATGCTGCTATCGAAAACGAACTGCCGTTCTAAAGGTTATCATGGCTGCTGTTCTGACTTCCGGTGAAGAAGGTAACGTCAGATCGAAAATCAAGCTGAAGGTTAAATCAAACGTTCTGTTGAAACCTCTAAAGAAAAACTGATCGAAGAAGGTAACGTCAGATCGAA
```

CGTGCTAAAGCTGACCTGGTTGGTAAACACCCCTGGAAGCCTTCGAGCTTCAAAAAGAACGTGAACTGGCTGAACGTATCTGGGACGAAATCGAAAAACTGCTGTCTtag

5) Theta+TEV

> TEV protease

Translation

MSLFKGPRDYNPISSSTICHLTNESDGHTTSLYGIGFGPFIITNKHLFRRN 50
NGTLLVQSLHGVFKVKNTTLQQHLIDGRDMIIIRMPKDFPPFPQKLKFR 100
EPQREERICLVTTFQTKSMSSMVSDTCTFPSSDGIFWKHWIQTKDQC 150
GSPLVSTRDGFIVGIHSASNFTNTNNYFTSPKKNFMELLTNQEAAQQWVSG 200
WRLNADSVLWGHHKVFMVKPEEPFQPVKREATQLMNELVYSQ

Improved DNA:

ATGTCTGTTCAAAGTCCCGTGACTACAACCGATCTCTTCTACCAT
100 TCGGTTTCGGTCCGTTCATCATCACCAACAAACACCTGTTCCGTCGTAAC
AACGGTACCTGCTGGTCAGTCTCTGCACGGTGGTCAAAGTTAAAAA
CACCACCAACCTGCAGCAGCACCTGATCGACGGTCGTGACATGATCATCA
TCCGTATGCCGAAAGACTTCCCAGCTTCCCGAGAAACTGAAATTCCGT
GAACCGCAGCGTGAAGAACGTATCTGCCTGGTTACCACCAACTTCCAGAC
CAAATCTATGTCTTCTATGGTTCTGACACCTTGCACCTCCGTCTT
CTGACGGTATCTTCTGGAAACACTGGATCCAGACCAAAGACGGTCAGTGC
GGTTCTCCGCTGGTTCTACCGTGACGGTTCATCGTTGGTATCCACTC
TGCTTCTAACTTACCAACACCAACTACTTCACCTCTGTTCCGAAAA
ACTTCATGGAACGTGCTGACCAACCAGGAAGCTCAGCAGTGGTTCTGGT
TGGCGTCTGAACGCTGACTCTGTTCTGTTGGGTGGTACAAAGTTTCT
GGTTAACCGGAAGAACCGTCCAGCCGGTAAAGAAGCTACCCAGCTGA
TGAACGAACTGGTTACTCTCAG

> ThetaTEV

TccggcgttagaggatcgagatcgatctcgatcccgcgaaattaatacgactcactatagggaaattgtgagcggataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattctctggctggccacgcgttctggatgaaagaaccgcgtgctAattcgaaacgccagcacatggacagccccagatctgggtacccgacgacgacgacaag

ATGTCTGTTCAAAGTCCCGTGACTACAACCGATCTTCTACCATGCCACCTGACCAACGAATCTGACGGTCACACCACCTCTGTACGGTATCGGTTCGTCCGTTCATCATACCAACAAACACTGTCGTAACAACGGTACCCGTCGGTTAGTC
CTGCACGGTGTTCAAAGTTAAAACACCACCACCCCTGCAGCAGCACCTGATCGACGGTCGTGACATGATCATCATCCGTATGCCGAAAGACTTCCGCCGTTCCCGCAGAAACTGAAATTCCGTGAACCGCAGCGTGAAGAACGTATCTGCTGGTTACCACCAACTCCAG
ACCAAATCTATGTTCTATGGTTCTGACACCTCTGCACCTCCCGTCTGTACGGTATCTTCTGGAAACACTGGATCCAGACCAAAGACGGTCAGTGCGGTCTCCGCTGGTTCTACCCGTGACGGTTCATGTTGGTATCCACTCTGTTCTAAC
AACAAACTACTCACCTCTGTTCCGAAAAACTTCATGGAAGCTGACCAACCAGGAAGCTCAGCAGTGGTTCTGGTGGCGTCTGAACGCTGACTCTGTTCTGTGGGGTGGTCACAAAGTTTATGGTTAACCGGAAGAACCGTCCAGCCGGTAAAGAAGCTACCCAG
CTGATGAACGAACGGTTACTCTCAGtag

6) Theta+SsoT

> Theta+SsoT

TccggcgttagaggatcgagatcgatctcgatcccgcgaaattaatacgactcactatagggaaattgtgagcggataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattctctggtctggccacgcggttctggatgaaagaaccgcgtcgtaattcgaaacgccacatggacagccccagatctggtaccgacgacgacgacaag

ATGGAAGAAAAGTTGTAACCTGAAACCGAACATGGAATCTGTTACCGTTCTGGAAAGCTCTGAAGCTCGCAGATCCAGACCAAAACGGTTCGTACCATCTGAAGCTATGTTGGTGACGAAACGGTCGTAAACTGACCCGTGGGTAAACCGCTGGTTCTATCAAAGAAGGTCAAGTTTAAATCGAAAACGCTGGACCACCGCTTCAAAGGTCAAGCTCAGCTGAACGCTGGTTCTAAACCAAAATCGCTGAAGCTCTGAAGACGGTTCCCGAATCTTCTCAGATCCCGAAACACCCGACCGCTCCGCAGCAGATGCGTGGTGGTGGTCGTGGTTCCCGTGGTGGTCGTACGGTCGTGGTGGTCGTCAAGAAAACGAAGAAGGTGAAGAAGAatag

7) Theta+ISO

> Theta+ISO

```
MEAKGEKPLEEMEFAIVDVITEEMLADKAALVVEVMEENYHDAPIVGIAL      50
VNEHGRFFMRPETALADSQFLAWLADETKKKSMFDAKRAVVALWKGIEL     100
RGVAFDLLLAAAYLLNPAQDGIAAVAKMKQEAVRSDEAVYGKGVKRSL     150
PDEQT LAELHVRKAAAIWALEQPFDMLRNNEQDQLLTKEHALAAILAE    200
MEFTGVNVDTKRLEQMGS LAEQLRAIEQRIYELAGQEFNINSPKQLGVI   250
LFEKLQLPVLKKTGTGSTSADVLEKLAPHHEIVENILHYRQLGKLQSTY   300
IEGLLVVVRPDTGVHTMFNQALTQTRGLSSAEPNLQNIPIRLEEGRKIR   350
QAFVPSEPDWLIFAADYSQIELRVLAHIADDNLIEAFQRDLIDIHTKTAM  400
DIFQLSEEEVTANMRRQAKAVNFGIVYGISDYGLAQNLNITRKEAAEFIE  450
RYFASFPGVKQYMENIVQEAKQKGYVTLLHRRRLPDITSRNFNVRSA    500
ERTAMNTPIQGSAADIKKAMIDLAARLKEEQLQARLLQVHDELILEAP    550
KEEIERLCELVPEVMEQAVTLRVPLKVDYHYGPTWYDAK
```

Improved DNA:

```
ATGGAAGCTAAAGGTGAAAAACCGCTGGAAGAAATGGAATTGCTATCGT      50
TGACGTTATCACCGAAGAAATGCTGGCTGACAAAGCTGCTGGTTGTTG      100
AAGTTATGGAAGAAAACTACCACGACGCCGATCGTGGTATCGCTCTG     150
GTTAACGAACACGGTCGTTCTTATGCGTCCGGAAACCGCTCTGGCTGA    200
CTCTCAGTTCTGGCTGGCTGGCTGACGAAACAAAAAAATCTATGT     250
TCGACGCTAACAGTGTGTTGCTGAAATGGAAGGTATCGAACTG          300
CGTGGTGTGCTTCGACCTGCTGCTGGCTGCTTACCTGCTGAACCCGGC  350
TCAGGACGCTGGTGACATCGCTGCTGGCTAAAGGTAAACAGTACGAAG  400
CTGTTCTGACGAAGCTGTTACGGTAAAGGTGTTAACAGTCTCTG        450
CCGGACGAACAGACCCCTGGCTGACACCTGGTCGTAAGCTGCTGCTAT  500
CTGGGCTCTGGAACAGCGTTCATGGACGACCTGCGTAACAACGAACAGG  550
ACCAGCTGCTGACCAAACCTGGAACACGCTCTGGCTGATCCTGGCTGAA  600
ATGGAATTCAACGGGTGTTAACGTTGACACCAAACGTCTGGACAGATGGG  650
TTCTGAACTGGCTGAACAGCTGCGTGCTATCGAACAGCGTATCTACGAAC 700
TGGCTGGTCAGGAATTCAACATCAACTCTCGAACACAGCTGGGTGTTATC 750
CTGTTGAAAAACTGCAGCTGCCGTTCTGAAAAAAACAAACCGGTTA       800
CTCTACCTCTGACGTTCTGGAAAACCTGGCTCCGACCCAGAAATCG     850
TTGAAAACATCCTGCACTACCGTCAGCTGGTAAACTGCAGTCTACCTAC  900
ATCGAAGGTCTGCTGAAAGTTGTTCCGGACACCGGTAAGATTACAC      950
CATGTTCAACCAGGCTCTGACCCAGACCGGCGTGTCTGCTGAAC        1000
CGAACCTGCAGAACATCCGATCCGTCTGGAAAGAAGGTGTTAACATCCGT 1050
CAGGCTTCGTTCCGCTGACCCGGACTGGCTGATCTCGCTGCTGACTA    1100
CTCTCAGATCGAACTGCGTGTGTTCTGGCTCACATCGCTGACGACGACAACC 1150
TGATCGAAGCTTCCAGCGTGACCTGGACATCCACACCAAAACCGCTATG  1200
GACATCTTCAGCTGCTGAAAGAAGTTACCGTAACATCGCTGCTCA      1250
GGCTAAAGCTGTTAACCTCGGTATCGTTACGGTATCTGACTACGGTC    1300
TGGCTCAGAACATCACCGTAAAGAAGCTGCTGAATTATCGAA        1350
CGTTACTTCGCTCTTCCGGGTGTTAACAGTACATGGAAAACATCGT    1400
TCAGGAAGCTAACAGAAAGGTTACGTTACCAACCGTGCACCGTCGTC  1450
GTTACCTGCCGGACATCACCTCTGTAACCTCAACGTTGCTTCTTCGCT  1500
GAACGTACCGCTATGAACACCCCGATCCAGGGTTCTGCTGACATCAT  1550
CAAAAAAGCTATGATCGACCTGGCTGCTGTGAAAGAAGAACAGCTGC  1600
AGGCTCGTCTGCTGCTGCAGGTTACGACGAACGATCCTGGAAAGCTCCG 1650
AAAGAAGAAATCGAACGTCTGCGAACCTGGTCCGGAGTTATGGAACAA 1700
```

GGCTGTTACCTCGTGTCCGCTGAAAGTTGACTACCACGACGCTCGA 1750
CCTGGTACGACGCTAAA

```
> Theta+ISO
TccggcgttagaggatcgagatcgatctcgatccgcgaaattaatacgactcactatagggaaattgtgagcggataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattttctggctggccacgcgt
tctggtatgaaagaaaccgcgtcgctAattcgaaacgccagcacatggacagccagatctgggtacccgacgacgacgacaag
```

ATGAAAGCTAAAGGTGAAAACCGCTGGAAGAAATTGCTATCGTGCAGTTACCGAAGAAATGCTGGCTGACAAAGCTGCTGGTTGAAGTTATGAAAGAAAATGCTGGCTCCGATCGTGGTATCGCTCTGGTTAACGAAACACGGTCGTTCTTC
ATGCGTCCGGAAACCGCTGGCTGACTCTCAGTCTGGCTGGCTGACGAAACCAAAAAAAATCTATGTCGACGCTAAACGTGCTGTTGCTGAAATGAAAGGTATCGAACTGCGTGGTGTGCTGGCTGCTAACCTGCTGAACCCG
GCTCAGGACGCTGGTGACATCGCTGCTGTTGCTAAACAGTACAAGCTGTTGACGAAGCTGGTAAAGGTGTTAACGTTCTGCCGGACGAACAGACCCGGCTAACACCTGGTCAAGCTGCTGCTATCTGGCTCTGGAACAGCCGTT
ATGGACGACCTGCGTAACAACGAACAGGACCAGCTGACCAAATGGAACACGCTCTGGCTGATCCTGGCTGAAATGGAATTACCGGTAAACGTTGACACCAAACGCTGGAACAGATGGTTCTGAACTGGCTAACAGCTGCGTCTATCGAACAGCGTATCTAC
GAACCTGGCTGGTCAGGAATTCAACATCAACTCTCGAAACAGCTGGGTGTTATCTGTTGAAAAACTGCAGCTGCCGGTCTGAAAAAAACCAAAACCGGTTACTCTACCTCTGCTGACGTTCTGGAAAAACTGGCTCCGACCACGAAATGTTGAAACATCCTGCACTAC
CGTCAGCTGGTAAACTGCAGTCTACCTACATCGAAGGTCTGCTGAAAGTTGTTCTGCCGGACACCGGTTAACGTTCACACCAGCTGTTCAACCAGGGCTCTGACCCAGACCGGTCGTTCTGCTGAACCGAACCTGAGAACATCCGATCCGCTGGAAGAAGGTGTT
ATCCGTCAGGCTTCGTCGCTGAAACGGACTGGCTGATCTCGCTGACTACTCTCAGATCGAACTGCGTGTCTGGCTCACATCGCTGACGACAAACCTGATCGAAGCTTCCAGCGTACCTGGACATCCACACCAAAACCGCTATGGACATCTTCAGCTGCT
GAAGAAGAAGTTACCGCTAACATCGCTGCTAGGCTAAAGCTGTTACCTCGGTATCGTTACGGTATCTGACTACGGTCTGGCTCAGAACATCACCGTAAAGAAGCTGCTGAAATTATCGAACTGTTCTTCCGGTAAACAGTACATGGAA
AACATCGTTAGGAAGCTAACAGAAAGGTTACGTTACCCCTGCTGCCGGACATCACCTCTGTAACCTCAACGTTGTTCTTCGCTGAAACGTTACCGCTATGAAACACCCGATCCAGGGTCTGCTGACATCATCAAAAGCTATGATC
GACCTGGCTGCTCGTCTGAAAGAAGAACAGCTGAGGCTCGTCTGCTGAGGTTACGACGAACGATCCTGGAAGCTCCGAAAGAAGAAATCGAACGTCTGCGAACACTGGTCCGGAAGTTATGAAACAGGCTGTTACCTGCTGAAAGTTGACTACCAC
TACGGTCCGACCTGGTACGACGCTAAATag

8) Theta+EXO

```

> Theta+EX0
MSKSWGKFIEEEEAEAMSRRNLMIVDGTNLGFRFKHNNSKKPFASSYVST      50  IQSLAKSYSARTTIVLGDKGKSVFRLPEYKGNRDEKYAQRTEEEKA
100 DEQFFEYLKDADFLCKTFPTFTIRGVEADDMAAYIVKLIGHLYDHVWL      150
STDGDWDTLLTDKVSRSFSFTTRREYHLRDMYEHHNVDDVEQFISLKAIMG      200
DLGDNIRGVEGIGAKRGYNIIREFGNVLIDQLPLPGKQKYIQNLNASE      250  ELLFRNLILVLDLPTYCVDAIAAVGQDVLDKFTKDILEIAEQ

```

Improved DNA:

ATGTCTAAATCTGGGTAATTCACTCGAAGAAGAAGAGTGAATGGC	50	TTCTCGTCGTAACCTGATGATCGTTACGGTACCAACCTGGTTCCGT
100 TCAAACACAACAACCTAAAAAACCGTTCGCTTCTTACGTTCTACC	150	
ATCCAGTCTCTGGCTAAATCTTACTCTGCTCGTACCAACATCGTTCTGGG	200	
TGACAAAGGTAATCTGTTTCCGTCTGGAACACCTGCCGGAATACAAAG	250	
GTAACCGTGACGAAAAATACGCTCAGCGTACCGAAGAAGAAGAAAAGCTCTG	300	
GACGAACAGTTCTCGAACCTGAAAGACGCTTCGAACTGTGAAAAC	350	
CACCTTCCCACCTCACCATCCGTGGTGTGAAGCTGACGACATGGCTG	400	
CTTACATCGTAAACTGATCGGTACCTGTACGACACGTTGGCTGATC	450	
TCTACCGACGGTACTGGGACACCCCTGCTGACCGACAAAGTTCTCGTT	500	
CTCTTCAACCACCGTCGTGAATACCACCTGCGTGACATGTACGAACACC	550	
ACAACGTTGACGACGTTAACAGTTCATCTCTGAAAGCTATCATGGGT	600	
GACCTGGGTGACAACATCCGTGGTGTGAAGGTATCGGTGCTAACGTGG	650	
TTACAACATCATCCGTGAATTGGTAACGTTCTGGACATCATCGACCAGC	700	
TGCCGCTGCCGGGTAACAGAAATACATCCAGAACCTGAAACGCTCTGAA	750	
GAACTGCTGTTCCGTAACCTGATCCTGGTTGACCTGCCGACCTACTGCGT	800	
TGACGCTATCGCTGCTGTTGGTCAGGACGTTCTGGACAAATTACCAAAAG	850	
ACATCCTGGAAATCGCTGAACAG		

>Theta+EXO

TccggcgtagaggatcgagatctcgatcccgaaattaatacgactcaactatagggaaattgtgagccgataacaattcccccttagaaataattTtgttaacttaagaaggagatacatatgcaccatcatcatcattcttggctggccacgcgt
tctggtatgaaagaaaccgctgctgctAaattcgaacgccagcacatggacagccagatctgggtaccgacgacgacgacaag

ATGCTAAATCTGGGTAAATTCACTGAAGAAGAAGCTGAAATGGTTCTCGTCGTAACCTGATGATCGTTGACGGTACCAACCTGGTTCCCAAACACAACACTCTAAAAACCGTCGCTCTTACGTTTCTACCATCCAGTCTGGCTAAATCTTAC
TCTGCTCGTACCAACCATCGTCTGGTGACAAAGGTAATCTGTTCCGCTGGAACACCTGCCGAATACAAAGGTAACCGTGACGAAAATACGCTCAGCGTACCGAAGAAGAAAAAGCTGGACGAACAGTTCTCGAATACCTGAAAGACGCTTCACTGCAA
ACCACCTTCCCACCTCACCATCGTGGTGAAGCTGACGACATGGCTGCTACATCGTAAACTGATCGGTACCTGACGACACGTTGGCTGATCTACCGACGGTACTGGGACACCGTGTGACCGACAAAGTTCTCGTTCTTACCCGTGAA
TACACCTCGTGCATGTACGAACACCAACGTTGACGACGTTGACAGTCTCTGAAAGCTATCATGGTGACCTGGGTGACAACATCCGTGGTGAAGGTATCGGTGCTAAACGTGGTACACATCATCCGTGAATTGGTAACGTTCTGGACATCATGAC
CAGCTGCCGCTGCCGGTAAACAGAAATACATCCAGAACCTGAACGCTCTGAAGAACTGCTGTTCGTAACCTGATCCTGGTGACCTGCCGACCTACTCGCTGACGCTATCGCTGTTGGTCAAGGACAAATTACCAAGACATCCTGGAAATCGCTGAA
CAGtag

9) Theta+LGT

> Theta+LGT

MTLEEARKRVNELRDLIRYHNYRYYVLADPEISDAEYDRLRELKEER 50
FPELKSPDSPTLQVGARPLEATFRPVHRPTRMYSLDNAFLDELKAFER 100
IERALGRKGPFAYTVEHKVDGLSVNLYEEGVLVYGATRGDGEVGEVTQ 150
NLLTIPTIPRRLKGVPERLEVRGEVYMPIEAFLRLNEELEERGERIFKNP 200
RNAAAGSLRQKDPRITAKRGLRATFYALGLGLEEVEREGVATQFALLHWL 250
KEKGFPEHGYARAVGAEGVEAVYQDWLKKRRALPFEADGVVVRDELAL 300
WRELGYTARAPRFAIAKYKPAEEKETRLLDVVFQVRTGRVTPVGILEPV 350
FLEGSEVSRTLHNESYIEELDIRIGDWLVHKAGGVIPEVRLVKERRT 400
GEERPIRWPETCPECGHRLLEGKVHRCPNPLCPAKRFEAIRHFASRKAM 450
DIQGLGEKLERLLEKGLVKDVADELYRLRKEDLVGLERMGEKSAQNLLRQ 500
IEESKKRGLERLLYALGLPGVGEVLARNLAARFGNMDRLEASLEELLEV 550
EEVGELTARAILETLKDPAFRDLVRRLKEAGVEMEAKEKGGEALKGLTFV 600
ITGELSRPREEVKALLRRLGAKVTDSVRKTSYLVVGENPGSKLEKARAL 650
GVPTLTEEELYRLLEARTGKKAELV

Improved DNA:

ATGACCCCTGAAAGAAGCTCGTAAACGTGTTAACGAACTCGTGACCTGAT 50 CCGTTACCACAACTACCGTTACTACGTTCTGGCTGACCCGGAAATCTCTG
100
ACGCTGAATACGACCGTCTGCTGCGTAACGAAACTGGAAAGAACGT 150
TTCCCGGAACGAAATCTCCGGACTCTCGACCCCTGCAGGTTGGTGCTCG 200
TCCGCTGGAAGCTACCTTCCGTCGGTCTGTCACCCGACCCGTATGTACT 250
CTCTGGACAACGTTCAACCTGGACGAACTGAAAGCTTCGAAGAACGT 300
ATCGAACGTGCTCTGGTCTGTAACCTGACTACGAAGAAGGTGTTCTGG 350
CAAAGTTGACGGTCTGTCTGTTAACCTGACTACGAAGAAGGTGTTCTGG 400
TTTACGGTCTACCCGTGGTGAAGTTGGTGAAGAAGTTACCCAG 450
AACCTGCTGACCATCCGACCATCCCGCGTCGTCGAAAGGTGTTCCCGA 500
ACGCTGGAAGTTCTGGTGAAGTTACATGCCGATCGAAGCTTCCCTGC 550
GTCTGAACGAAGAACGTGGAAGAACGTGGTGAACGTATCTTAAAAACCG 600
CGTAACGCTGCTGGTTCTCGTCAGAAAGACCCCGTATCACCAC 650
TAAACGTGGTCTCGTGCTACCTTCTACGCTCTGGGTCTGGGTCTGGAAG 700
AAGTTGAACGTGAAGGTGTTGCTACCCAGTTCGCTCTGCTGACTGGCTG 750
AAAGAAAAAGGTTCCGGTTGAACACGGTTACGCTCGTGTGTTGGTGC 800
TGAAGGTGTTGAAGCTGTTACCGAGCTGGCTGAAAAACGTCGTGCTC 850
TGGCGTGAAGCTGGGTTACACCGCTCGTCTCGCGTTCGCTATCGCTTA 900
CAAATTCCCGGCTGAAGAAAAAGAAACCGTCTGCTGGACGTTGGTTC 950
AGGTTGGTCTGACCGGTTACCCGGTTGGTATCCTGGAAACCGGTT 1000
1050

TTCTGGAAAGGTTCTGAAGTTCTCGTGTACCCGCACAAACGAATCTTA 1100
CATCGAAGAACCTGGACATCCGTATCGGTACTGGTTCTGGTTACAAAG 1150
CTGGTGGTGTATCCCGGAAGTTCTCGTGTCTGAAAGAACGTCGTACC 1200
GGTGAAGAACGTCGATCCGTTGGCCGGAAACCTGCCCGGAATCGGGTCA 1250
CCGTCTGCTGAAAGAACGTTAACGTTACCGTTGCCGAACCCGCTGTGCC 1300
CGGCTAAACGTTCGAAGCTATCCGTACTCGCTCTCGTAAAGCTATG 1350
GACATCCAGGGTCTGGGTAAAAACTGATCGAACGTCGCTGGAAAAAGG 1400
TCTGGTTAAAGACGTTGCTGACCTGTACCGTCTCGTAAAGAACCTGG 1450
TTGGTCTGGAACGTATGGGTAAAAACTGCTCAGAACCTGCTGCGTCAG 1500
ATCGAAGAACATCTAAAAACGTGGTCTGGAACGTCGCTGTACGCTCTGGG 1550
TCTGCCGGGTGTTGGTGAAGTTCTGGCTCGTAACCTGGCTGCTCGTTCG 1600
GTAACATGGACCGTCTGCTGGAAAGCTTCTCGGAAAGAACGTCGTTGG 1650
GAAGAACGTTGGTGAACTGACCGCTCGTCTGAAAGAACGTCGTTGGAAA 1700
CCCGGCTTCCGTGACCTGGTCTCGTCTGAAAGAACGTCGTTGGAAA 1750
TGGAACGCTAAAGAAAAAGGGGGTGAAGCTCTGAAAGGTCGACCTTCGTT 1800
ATCACCGGTGAACGTCTCGTCCCGTGAAGAACGTTAAAGCTCTGCTGCG 1850
TCGTCTGGGTGCTAAAGTTACCGACTCTGTTCTCGTAAACCTCTTACC 1900
TGGTTGGTGGTGAACCGGGTTCTAAACTGGAAAAAGCTCGTCTG 1950
GGTGTCCGACCCCTGACCGAAGAACGTCGACCTGCTGGAAAGCTCG 2000
TACCGGTAAAAAGCTGAAGAACGTCGTT

> Theta+LGT

TccggcgttagaggatcgagatcgatctcgatccccgcaaattaatacgactcactatagggaaattgtgagcggataacaattccctctagaataattTtgttaactttaagaaggagatatacatatgcaccatcatcatcattctctggtctggccacgcggttctggatgaaagaaccgcgtgctgctaattcgaaacgccagcacatggacagccagatctgggtacccgacgacgacgacaag

ATGACCCCTGGAAGAAGCTCGTAAACGTGTTAACGAACTGCGTGACCTGATCCGTTACCACAACCTACCGTTACTACGGTCTGGCTGACCCGAAATCTCTGACGCTGAATACGACCGCTGCTGCGTAACGAAACTGAAAGAACGTTCCGGAACTGAAATCTCCGGAC
TCTCCGACCCCTGCAGGTTGGTCTCGTCCGCTGGAAGCTACCTCCGTCGGTTCGTACCCGACCCGTATGTAACCTCTGGACAACGCTTCAACCTGGACGAACGTTGAAAGCCTTGAAAGAACGTTACGAAACGCTGCTGGGCGTAAAGGTCGTTACCCGTTGAA
CACAAAGTTGACGGTCTGTCGTTAACCTGACTACGAAGAAGGTGTTCTGGTTACGGTCTACCCGTTGGTGAAGGTTACCCAGAACCTGCTGACCATCCCGACCATCCCGCTGCTGAAAGGTTCCGGAAACGTCGTTGAAAGGTTGTTGAA
GTTTACATGCCGATCGAAGCTTCCGCTCTGCGTCTGAAACGAAGAACGTTGGAACGTTGAAACGTTACCCGCGTAAACGCTGCTGCTGGTTCTGCGTCAGAAAGACCCGCTATCACCCTAAACGTTGCTGCTACCTCTACGCTCTGGGCTGGGCTG
GAAGAAGTTGAAACGTGAAGGTTGCTACCCAGTTGCTCTGCTGACTGGCTGAAAGAAAAAGGTTCCGGTTAACACGGTTACGCTCGTGTGCTGGTGAAGGTTGAAAGCTGTTACAGGACTGGCTGAAAGGTTACGCGTCTGCCGTTGAAAGCTGACGGT
GTTGTTGTTGCTCTGGACGAACTGGCTCTGTTGGCGTGAACGGTTACCCGCTCGTGTGCTCCGCTTCTGCTATCGTTACAAATTCCCGCTGAAAGAAAAAGAACCCGCTGCTGGACGTTGTTCCAGGTTGGTGTACCGGCTGTTACCCGGTTGGTATCCTGGAA
CCGGTTTCCGGAAGGTTCTGAAAGTTCTGTTACCCGTCACAACGAATCTTACATCGAAGAACGTTGACATCCGTTGACTGGGTTCTGGTTACAAAGCTGGGTTGTTATCCCGGAAGGTTCTGCGTGTGAAAGAACGTCGTAACGGTGAAGAACGTCGATC
CGTTGGCCGAAACCTGCCCGAATGCGGTACCGTCTGCTGAAAGAACGTTACCGGTTGCCGAACCCGCTGTGCCGGCTAACGTTGAAAGCTATCCGTCACCTCGCTTCTGTAAGCTATGGACATCCAGGGCTGGGTGAAAAGACTGATCGAACGCTGCTG
GAAAAAGGTCTGGTTAAAGACGTTGCTGACCTGACCGTCTGCTGAAAGAACGTTGGGTTGGTCTGGAAACGTTGGGTTGAAAATCTGCTCAGAACCTGCTGCGTCAGATCGAAGAACGTTACGGGTTCTGGGCTGGGTTGGTCTGGGTTGGTCTGGGTTGGT
GAAGTTCTGGCTCGTAACCTGGCTGCTCGTTGGTAAACATGGACCGCTGCTGGAAGAACGTTCTGGAAGAACGTTGAAAGAACGTTGGGTTGAACTGACCGCTCGTGTGCTATCTGGAAACCCCTGAAAGAACCCGGTTCCGTCACCTGGGTTGCTG
GGTGTGAAATGGAAGCTAAAGAAAAAGGTGGTGAAGCTCTGAAAGGCTGACCTCGTTACCGGTTGAACTGTCGTCGCTGGTGAAGAACGTTAAAGCTCTGCTGCGTCGTTGGGTTGCTAAAGTTACCGACTCTGTTCTGTAACCTTACCTGGTTGGTGA
AACCCGGGTTCTAAACTGGAAAAAGCTGCTCGTCTGGGTTCCGACCCGACCGAAGAACGTTACCGTCTGCTGGAAGCTGCTACCCGTTAAAGCTGAAAGAACGTTGTTtag

References

2004. Nucleic Acids Res. 32(3):1197-207. PMID: 14973201
1998. Acta Biochim Pol. 45(3):653-60. PMID:9918481
2002. Proc Natl Acad Sci USA. 99(2): 596-601. PMID: 1178252
2014. Mol Biol Int. 2014:287430. PMID:25197572
2022. ACS Catalysis. 2022, 12, XXX, 2988-2997
2002. Mol Microbial. 43(6):1505-15. PMID: 11971263
1989. Virology. 172(1):302-10. PMID:2475971
2018. Nat Biotechnology. 36(7):645-450. PMID:29912208
2002. Mol Microbial. 43(6):1505-15. PMID: 11971263
1991. Gene. 108(1):1-6. PMID: 1761218
1976. J Bacteriol. 127(3):1550-7. PMID: 8432
1977. Biochim Biophys Acta. 475(1):32-41
1999. Proc Natl Acad Science USA. 96(1):38-43. PMID: 987476
1996. Nucleic Acids Res. 24(15):3071-8
<https://openbioeconomy.org/projects/open-enzyme-collections>